[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369617-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369617-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","risk-of-new-or-recurrent-cancer-during-treatment-with-biologics-in-patients-with-immune-mediated-inflammatory-diseases-and-previous-cancer-a-meta-analysis","Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory diseases and previous cancer - a meta-analysis","","Biologics improve treatment of immune-mediated inflammatory diseases (IMIDs), yet most product labels warn against use in patients with active cancer or a history of cancer. This systematic review and meta-analysis assessed the risk of new and/or recurrent cancer in IMID patients with prior cancer receiving biologics. Searches of PubMed, Embase, Cochrane Library, and Web of Science (to Feb 23, 2024) were conducted versus controls. Twenty articles (4736 patients; 15,646 patient-years) were included. Tumor necrosis factor (TNF)-α inhibitors, IL-12/23 inhibitors, and vedolizumab showed no apparent increased risk compared with conventional systemics or no therapy; results support shared decision-making, while further evidence on newer biologics is needed.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/risk-of-new-or-recurrent-cancer-during-treatment-with-biologics-in-patients-with-immune-mediated-inflammatory-diseases-and-previous-cancer-a-meta-analysis/369617/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/risk-of-new-or-recurrent-cancer-during-treatment-with-biologics-in-patients-with-immune-mediated-inflammatory-diseases-and-previous-cancer-a-meta-analysis/369617.png","ImageObject",300,407,{"name":42,"@type":43},"Aditya","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why was there reluctance to prescribe biologics to patients with a history of cancer?","Question",{"text":63,"@type":64},"Most biologics carry warnings for patients with active cancer or a history of cancer, which led to reluctance and limited evidence on cancer recurrence risk in this population.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What did the meta-analysis find about the risk of new or recurrent cancer with biologics?",{"text":68,"@type":64},"TNF-α inhibitors, IL-12/23 inhibitors, and vedolizumab did not appear to increase the risk of new or recurrent cancer compared with conventional systemics or no therapy.",{"name":70,"@type":61,"acceptedAnswer":71},"Which databases and time range were searched for included studies?",{"text":72,"@type":64},"The review searched PubMed, Embase, Cochrane Library, and Web of Science up to February 23, 2024.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369617,1790230111,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Clinical and Experimental Medicine (2025) 25:219 [https://doi.org/10.1007/s10238-025-01738-4](https://doi.org/10.1007/s10238-025-01738-4)  \nRisk of new or recurrent cancer during treatment with biologics in patients with immune‑mediated inflammatory diseases and previous cancer: a meta‑analysis  \nDaniel Isufi1,2 · Christopher Willy Schwarz1,2,3 · Mikkel Bak Jensen3,4 · Jakob Seidelin3,5 · Lone Skov1,2,3 · Nikolai Loft1,2  \nReceived: 28 February 2025 / Accepted: 18 May 2025 / Published online: 25 June 2025 © The Author(s) 2025  \nAbstract  \nWhile biologics have proven to be effective in treating immune-mediated inflammatory diseases (IMIDs), the label of most biologics carries a warning regarding their use in patients with active cancer or a history of cancer. Consequently, there has been a reluctance to prescribe these medications to patients with a history of cancer, and little is known about the risk of new and/or recurrent cancer in patients with IMIDs treated with biologics and a previous cancer. This systematic review and meta-analysis searched PubMed, Embase, Cochrane Library, and Web of Science up to February 23, 2024, for studies on the risk of new and/or recurrent cancer following treatment with biologics in patients with IMIDs and a previous cancer compared to controls (PROSPERO; CRD42024516899). Controls included patients receiving non-biological or no therapy. Risk estimates were calculated with random-effects meta-analysis with I2 statistics to estimate between-study heterogeneity. In total, 20 articles comprising 4736 patients treated with biologics with 15,646 patient-years of follow-up were included. Treatment with tumor necrosis factor (TNF)-α inhibitors (TNFi), interleukin (IL)-12/23 inhibitors or vedolizumab did not appear to lead to increased risk of new or recurrent cancer in patients with IMIDs and a previous cancer compared to conventional systemics or no therapy. The results are reassuring to patients and physicians prescribing biologics to patients with IMIDs. However, further studies are needed especially on newer biologics and decision on initiation of biologics in patients with cancers should be based on an individual assessment.  \nKeywords Adalimumab · Infliximab · Psoriasis · Mb Crohns · Colitis ulcerosa · Rheumatoid arthritis  \n* Nikolai Loft [nikolai.nguyen.loft@regionh.dk](nikolai.nguyen.loft@regionh.dk)  \n1 Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark  \n2 Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital, Herlev, Denmark  \n3 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark  \n4 Department of Dermatology and Allergy, National Allergy Research Centre, Herlev and Gentofte Hospital, Herlev, Denmark  \n5 Department of Digestive Diseases and Transplantation, IBD Section, Rigshospitalet, Copenhagen, Denmark  \nIntroduction  \nSince their introduction, some biologics have been used for treatment of several immune-mediated inflammatory diseases (IMIDs) by inhibition of inflammatory markers such as tumor necrosis factor (TNF), interleukin (IL)-17, IL-6, IL-12/23, IL-23 and the gut-selective α4β7-integrin [1–6] . While biologics have proven effective in the treatment of IMIDs including psoriasis, psoriatic arthritis (PsA), rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) [7–10], concerns about a potential increased risk of cancer, particularly for TNF-α inhibitors (TNFi), have been raised [11, 12] . The label of most biologics carries a warning regarding their use in patients with active cancer or a history of cancer. Consequently, there has been a reluctance to prescribe these medications to patients with a history of cancer [13] . Ultimately, this might lead to confounding by indication where patients with higher risk of cancer recurrence being prescribed conventional  \nsystemics. However, studies examining the carcinogenic properti","cbCaisaPGoAjSJzn","https://ap.wps.com/l/cbCaisaPGoAjSJzn","pdf",1707853,12,"English","# Abstract\n# Introduction\n# Materials and methods\n## Search strategy and selection criteria","[{\"question\":\"Why was there reluctance to prescribe biologics to patients with a history of cancer?\",\"answer\":\"Most biologics carry warnings for patients with active cancer or a history of cancer, which led to reluctance and limited evidence on cancer recurrence risk in this population.\"},{\"question\":\"What did the meta-analysis find about the risk of new or recurrent cancer with biologics?\",\"answer\":\"TNF-α inhibitors, IL-12/23 inhibitors, and vedolizumab did not appear to increase the risk of new or recurrent cancer compared with conventional systemics or no therapy.\"},{\"question\":\"Which databases and time range were searched for included studies?\",\"answer\":\"The review searched PubMed, Embase, Cochrane Library, and Web of Science up to February 23, 2024.\"}]","Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory diseases and previous cancer - a meta-analysis | PDF",1790183693,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68ea79077d3544f8bfb77e19fbc5a5fb.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c376a5d6bed2f813f9e2b8f530002f8.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35ce376a451ec46abde58a5f5fd78d4a.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/381fa2fc2cd3423229356dd5b1f5e256.webp",980,1301]